% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

  • groovygeek_3142 groovygeek_3142 Feb 7, 2012 10:45 PM Flag

    2011-Q4 earnings

    Hmm, earnings have been out for 6-7 hrs now and no discussion here. Sounds like we have a whole lot of speculators around here and not many who care about the longer-term picture.

    Revenue up sequentially ~20%, loss down ~25%, and that included $5M RIF costs. Assuming that this is behind them and the trends remain in place you are looking at sub-$18M losses in Q1'12 and sub-$10M by the end of the year. Barring any major disruption in the marketplace these are manageable trends.

    The most significant concern is the ever-declining backlog, and only six new bookings. I am away from my historical information, but it seems that they shipped A LOT more instruments in Q4 than usual (17 vs 7-8 in Q3). On one hand the positive is that orders keep coming in, which seems that there is SOME demand in the market place for their tool. On the other hand the declining backlog does not bode well. This is probably one of the bigger commercial risks to PACB at this time, as well as what OxNano says at AGBT. Anything close to full genome sequencing and PACB all of a sudden is in serious hot water.

    My connection is slow as molasses, anything of note on the conference call?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.56-0.29(-3.28%)Aug 24 4:00 PMEDT